Half of hepatitis C patients with private insurance denied life-saving drugs

The number of insurance denials for life-saving hepatitis C drugs among patients with both private and public insurers remains high across the United States. Private insurers had the highest denial rates, with 52.4 percent of patients denied coverage, while Medicaid denied 34.5 percent of patients and Medicare denied 14.7 percent.